BNET Industries

Last Fiscal Year Sales:$750.0K
  • Private
  • US
Dow Jones Description

Flamel Technologies is a drug delivery company with expertise in polymer chemistry. The company was founded in 1990. In 1996, Flamel Technologies (FLML) became the second French biotech company to enter the Nasdaq. The Company has assembled a strong team of researchers expert in polymer science and biochemistry, and owns cGMP pharmaceutical production facility of over 100,000 square feet located in Pessac, France (with an annual production capacity of 2 billion tablets or capsules). Flamel's drug delivery platforms, Medusa for therapeutic proteins and peptides, and Micropump for small molecules , have been developed to improve the therapeutic characteristics, safety profile and ease of use of wide variety of drugs. The Company is a recognized world leader in the innovation of delivery systems for small molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners. Flamel has partnership agreements with major pharmaceutical companies:

Chief Executive Officer
Stephen H Willard
Number of Employees 2
Contact Information

District of Columbia

www.flamel.com

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to...

    11/16/09 - Financial Announcement - View Story

  • xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 4, 2009 : FLML, XING, AFFY and MOCO

    11/05/09 - Joint Venture / Alliance - View Story

  • Flamel Technologies Announces Second Quarter 2009 Results; Multiple New Projects; Cash Increases from $39.1 to...

    8/05/09 - Financial Announcement - View Story

News & Analysis

flamel technologies - All News and Analysis

Decision Makers

Name (plus bio) Position
Stephen H Willard Chief Executive Officer
Christian Kalita Directeur General Delegue Pharmacien Responsable (Chief Pharmacist)
Jeffery S. Vick Chief Business Officer
Rafael Jorda Chief Operating Officer, Executive Vice President, Director of Manufacturing and Development
Andrew Francis Vice President Business Development
Catherine Castan Director of R&D Micropump, Head of Micropump Team
Charles Marlio Director of Strategic Planning and Investor Relations
Charles Mosseri-Marlio Director of Strategic Planning and Investor Relations
David Weber Director of Purchasing Operations
Katherine Hanras Director of Innovative Technologies
Kenneth Lundstrom Director of Research
Martine Capelle Human Resources Director
Nigel McWilliam Director, Business Development, USA
Remi Meyrueix Scientific Director
Roger Kravtzoff Preclinical and Early Clinical Development Director
Sian Crouzet Controller, Administrative and Financial Director
Nicolas Flamel
Raphaelle Portella Legal Counsel, France
WILLIAM DEARSTYNE Member

Board of Directors

Name (plus bio) Position
Elie Vannier Chairman (Chief Operating Officer of Grandvision Sa)
John L. Vogelstein Director (Vice Chairman of Warburg Pincus)
Frederic Lemoine Director (Chairman of the Supervisory Board of Areva)
Christian Trepo Board of Directors
Yves Bourboulou Board of Directors

Organization Position Status
Flamel Technologies Incorporated Chief Executive Officer Current
Flamel Technologies Incorporated President Former
Biovail Corporation Vice President Former
Shearman & Sterling Llp Attorney Former
Gibson, Dunn & Crutcher LLP Attorney Former
Yale Law School Former
Williams College Former

Organization Position Status
Flamel Technologies Incorporated Directeur General Delegue Pharmacien Responsable (Chief Pharmacist) Current
Skyepharma, Inc. Director of Quality Former

Organization Position Status
Flamel Technologies Incorporated Chairman (Chief Operating Officer of Grandvision Sa) Current

Jeffery Vick is our Chief Business Officer. Mr. Vick has more than 20 years experience in the business and research side of the biotechnology industry in both Europe and the US. Prior to joining Flamel, Mr. Vick was Chief Executive Officer of Silence Therapeutics. Mr Vick previously held senior management positions with Centelion SAS, a wholly-owned subsidiary of Aventis, Genset SA, Cytovia, Inc, and DepoTech Corporation and worked with Sanderling Venture Capital for two years. Mr Vick holds an MBA from Stanford, an MS Chemistry from the University of California, San Diego, and a BS Chemistry from the University of Virginia.

Organization Position Status
Flamel Technologies Incorporated Chief Business Officer Current
Stanford University MBA Former

Organization Position Status
Flamel Technologies Incorporated Chief Operating Officer, Executive Vice President, Director of Manufacturing and Development Current
Virginia Polytechnic Institute and State University Masters In Chemical Engineering Former

Organization Position Status
Flamel Technologies Incorporated Vice President Business Development Current
Skyepharma, Inc. Group Vice President for Business Development Former

Organization Position Status
Flamel Technologies Incorporated Director of R&D Micropump, Head of Micropump Team Current
Flamel Technologies Incorporated Board of Directors Current

Organization Position Status
Flamel Technologies Incorporated Director of Strategic Planning and Investor Relations Current

Organization Position Status
Flamel Technologies Incorporated Director of Strategic Planning and Investor Relations Current

Organization Position Status
Flamel Technologies Incorporated Director of Purchasing Operations Current
Flamel Technologies Incorporated Board of Directors Current

Organization Position Status
Warburg, Pincus, LLC Managing Director, New York Current
Warburg Pincus, LLC Vice Chairman & Managing Director Current
Flamel Technologies Incorporated Director (Vice Chairman of Warburg Pincus) Current
New York University Trustee Current
Flamel Technologies Incorporated Board of Directors Current
New Providence Asset Management Limited Chairman Current
Prep,Inc. Chairman of the Board of Directors Current
Journal Register Company Board of Directors Current
The Jewish Museum Board of Directors Current
Sharegift USA Board of Directors Current
New York City Ballet Director Current
Warburg, Pincus, LLC Vice Chairman, New York Current
NYU Stern School of Business Vice Chairman Current
Piedmont Natural Gas Company, Inc. Vice Chairman Current
Flamel Technologies, S.A. Board of Directors Current
Americans for Gun Safety Board of Directors Current
Ags Foundation Board of Directors Current
Congregation Emanu-El Board of Directors Current
Third Way Board of Directors Current
The Jewish Museum Trustee Current
Congregation Emanu-El Trustee Current
Third Way Trustee Current
Lazard Ltd. Partner Former
Mattel, Inc. Board of Directors Former
Information Holdings Inc. Board of Directors Former

Organization Position Status
Flamel Technologies Incorporated Director of Innovative Technologies Current

Kenneth Lundstrom joined Flamel in June 2006 as Director of Research. Dr. Lundstrom is a molecular biologist by training and has acquired a broad expertise in protein expression, viral vectors, gene therapy, structural genomics and drug delivery. He has published more than 200 peer-reviewed research articles, reviews and book chapters. Previously, Dr. Lundstrom has worked for both big pharmaceutical companies and start-up biotechnology enterprises.

Organization Position Status
Flamel Technologies Incorporated Director of Research Current
Flamel Technologies Incorporated Board of Directors Current

Organization Position Status
Flamel Technologies Incorporated Human Resources Director Current

Organization Position Status
Flamel Technologies Incorporated Director, Business Development, USA Current
Flamel Technologies Incorporated Board of Directors Current
University of Dundee Bachelors Degree In Science Former

Organization Position Status
Flamel Technologies Incorporated Scientific Director Current
Flamel Technologies Incorporated Board of Directors Current
RhOne-Poulenc Former

Organization Position Status
Flamel Technologies Incorporated Preclinical and Early Clinical Development Director Current
Flamel Technologies Incorporated Board of Directors Current

Organization Position Status
Flamel Technologies Incorporated Controller, Administrative and Financial Director Current
Flamel Technologies Incorporated Principal Financial Officer Current

The story of this alchemist, as handed down by tradition, and enshrined in the pages of Lenglet du Fresnoy, is not a little marvelous. He was born at Pontoise of a poor but respectable family, at the end of the thirteenth, or beginning of the fourteenth, century. Having no patrimony, he set out for Paris at an early age, to try his fortune as a public scribe. He had received a good education, was well skilled in the learned languages, and was an excellent penman. He soon procured occupation as a letter-writer and copyist, and used to sit at the corner of the Rue de Marivaux, and practice his calling: but he hardly made profits enough to keep body and soul together. To mend his fortunes he tried poetry; but this was a more wretched occupation still. As a transcriber he had at least gained bread and cheese; but his rhymes were not worth a crust. He then tried painting with as little success; and as a last resource, began to search for the philosopher's stone, and tell fortunes. This was a happier idea; he soon increased in substance, and had wherewithal to live comfortably. He, therefore, took unto himself his wife Petronelle, and began to save money; but continued to all outward appearance as poor and miserable as before. In the course of a few years, he became desperately addicted to the study of alchemy, and thought of nothing but the philosopher's stone, the elixir of life, and the universal alkahest. In the year 1257, he bought by chance an old book for two florins, which soon became the sole study and object of his life. It was written with a steel instrument upon the bark of trees, and contained twenty-one, or as he himself always expressed it, three times seven, leaves. The writing was very elegant and in the Latin language. Each seventh leaf contained a picture and no writing. On the first of these was a serpent swallowing rods; on the second, a cross with a serpent crucified; and on the third, the representation of a desert, in the midst of which was a fountain with serpents crawling from side to side. It purported to be written by no less a personage than "Abraham, patriarch, Jew, prince, philosopher, priest, Levite, and astrologer;" and invoked curses upon any one who should cast eyes upon it, without being a priest or a scribe. Nicholas Flamel never thought it extraordinary that Abraham should have known Latin, and was convinced that the characters on his book had been traced by the hands of that great patriarch himself. He was at first afraid to read it, after he became aware of the curse it contained; but he got over that difficulty by recollecting that, although he was not a priest, he had practiced as a scribe. As he read he was filled with admiration, and found that it was a perfect treatise upon the transmutation of metals. All the process was clearly explained; the vessels, the retorts, the mixtures, and the proper times and seasons for the experiment. But as ill-luck would have it, the possession of the philosopher's stone or prime agent in the work was presupposed. This was a difficulty which was not to be got over. It was like telling a starving man how to cook a beefsteak, instead of giving him the money to buy one. But Nicholas did not despair; and set about studying the hieroglyphics and allegorical representations with which the book abounded. He soon convinced himself that it had been one of the sacred books of the Jews, and that it was taken from the temple of Jerusalem on its destruction by Titus. The process of reasoning by which he arrived at this conclusion is not stated. From some expression in the treatise, he learned that the allegorical drawings on the fourth and fifth leaves, enshrined the secret of the philosopher's stone, without which all the fine Latin of the directions was utterly unavailing. He invited all the alchemists and learned men of Paris to come and examine them, but they all departed as wise as they came. Nobody could make anything either of Nicholas or his pictures; and...

Organization Position Status
Flamel Technologies Incorporated Current

Organization Position Status
Flamel Technologies Incorporated Legal Counsel, France Current

Organization Position Status
Flamel Technologies Incorporated Director (Chairman of the Supervisory Board of Areva) Current
Flamel Technologies Incorporated Board of Directors Current

Organization Position Status
Flamel Technologies Incorporated Board of Directors Current

Organization Position Status
Flamel Technologies Incorporated Board of Directors Current
Pharmacia Corporation Manager Former

Organization Position Status
Phonak AG Member Current
Flamel Technologies Incorporated Member Current
Earlybird LLC Advisor Current
Earlybird LLC Board of Directors Current
Johnson & Johnson Company Group Chairman Former
advertisement
Click Here
advertisement